

Background on FDA Commissioners

Michael A. Friedman

(Clinton)

- currently senior vice president of clinical affairs for Pharmacia Corporation, a member of PhRMA (Source: The Pink Sheet," 09/04/00)

James Benson

(Bush)

- executive vice president, technology & regulatory affairs, of Advanced Medical Technology Association (formerly Health Industry Manufacturers Association)

Mark Novitch

(Acting Commissioner, Reagan)

- currently Chairman of Alteon Inc. pharmaceutical company
- 1985-1993, Vice Chairman and Chief Compliance Officer of The Upjohn Company (now Pharmacia & Upjohn, Inc.), a member of PhRMA
- Serves on board of directors of Neurogen Corporation, a pharmaceutical company
- Serves on board of directors of Guidant (designs and develops cardiovascular medical devices)

Arthur Hull Hayes

(Reagan)

- Former President and CEO of EM Pharmaceuticals, a North American Subsidiary of E. Merck
- President and Chief Operating Officer of MediScience Associates, Inc., a consulting organization he founded in 1991 that works with pharmaceuticals firms.
- Vice Chairman, Medical Director, and Member of Board of Directors of Nelson Communications Inc., an associate member of PhRMA
- Is also director of: NaPro BioTherapeutics, Inc., a natural product pharmaceutical company, and Celgene Corporation, a pharmaceutical company.
- Serves on Scientific and Medical Advisory Board of Entropin, Inc., a pharmaceutical company

Jere Goyan

(Carter)

- currently President and Chief Operating Officer of Alteon Inc. pharmaceutical company
- Serves as Chairman of the Board of SciClone Pharmaceuticals
- currently serves as a director of Penwest Pharmaceutical Company, a research affiliate

of PhRMA

Donald Kennedy

(Carter)

- current editor-in-chief of Science
- president emeritus of Stanford University (1980-1992).
- Stanford University has strong ties to the biotech industry. Professor Stanley Cohen of Stanford and Professor Herbert Boyer of the University of California developed basic gene splicing (recombinant DNA) patents that "gave rise to the entire biotechnology industry." Prior to the expiration of the Cohen-Boyer patents in 1997, Stanford received \$37.3 million in royalties from rDNA licenses in 1997-98. (Source: "Annual Report 1998-99," Stanford University Office of Technology Licensing, and "A History of OTL Overview," Wiesendanger, Hans, Senior Licensing Associate, Stanford University Office of Technology Licensing.)

Charles Edwards

(Nixon)

- 1975-1977, executive with a medical device firm
- 1991-present, president and CEO of the Scripps Institutes for Medicine and Science - suspect licensing agreements with drug industry but cannot confirm

James L. Goddard

(Johnson)

- left FDA in 1968 for a position with a medical/industrial systems analysis firm, EDP Technology, Atlanta, GA

Frank E. Young

(Reagan, Bush)

- Testified against the Prescription Drug Marketing Act when he was FDA Commissioner in 1986. To quote Mr. Young's testimony: "While your bill [H.R. 4820, a bill which would ban the reimportation of drugs produced in the United States] would make it more difficult to introduce adulterated and misbranded drugs; however, there are existing laws and programs in place and working to deal with such actions. Furthermore, there is little hard evidence that significant health problems have actually occurred as a result of these practices."